Our UHN programs and services are among the most advanced in the world. We have grouped our physicians, staff, services and resources into 10 medical programs to meet the needs of our patients and help us make the most of our resources.
University Health Network is a health care and medical research organization in Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international source for discovery, education and patient care.
Our 10 medical programs are spread across eight hospital sites – Princess Margaret, Toronto General, Toronto Rehab’s five sites, Toronto Western – as well as our education programs through the Michener Institute of Education at UHN. Learn more about the services, programs and amenities offered at each location.
Maps & Directions
Find out how to get to and around our nine locations — floor plans, parking, public transit, accessibility services, and shuttle information.
Ways You Can Help
Being touched by illness affects us in different ways. Many people want to give back to the community and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one of our experts for an interview. It’s also the place to find UHN media policies and catch up on our news stories, videos, media releases, podcasts and more.
You are looking at a strip of muscle, about the size of a grain of rice, suspended between two very fine wires. Despite its cylindrical shape, it is a miniature version of the human heart, and contracts and relaxes with the same hypnotic rhythm.
This feat was achieved by a team of researchers led by Drs.
Milica Radisic and
Peter Backx, Senior Scientists at the Toronto General Hospital Research Institute. Because their miniature heart closely mimics the cells found in a real heart, it may be a game changer in the study of heart disease and the search for therapeutic drugs.
The human heart has two types of chambers – atria and ventricles – that have different functions and are made of different kinds of cells. Because of this, atrial cells, which make up atria, and ventricular cells, which make up ventricles, respond to drugs differently.
While abnormal beating of the atria is the most common heart defect implicated in heart failure, up until recently, researchers had only been able to make ventricular tissues from human pluripotent stem cells.
The breakthrough platform engineered by Dr. Radisic and her colleagues, named Biowire II, is capable of growing both atrial and ventricular tissues. These atrio-ventricular Biowires have atrial cells on one end and ventricular cells on the other end, and have the same mechanical properties as real heart tissue.
"Biowires grown from the cells of healthy hearts are distinct from those grown from the cells of abnormal hearts," describes Dr. Radisic. "This enables us to model various heart conditions in the lab."
The Biowires also captured the effect of the drug ranolazine on the heart. Ranolazine is currently used to treat chest pain caused by insufficient blood supply to the heart.
With engineered tissues that resemble real hearts such as the Biowire II, researchers are one step closer to understanding the progression of heart disease and developing drugs that target specific heart cells without harming others.
This work was supported by the Canadian Institutes of Health Research, the Natural Sciences and Engineering Research Council of Canada, the U.S. National Institutes of Health, the Ted Rogers Centre of Heart Research, and the Toronto General & Western Hospital Foundation. Dr. Brian Cox holds a Tier 2 Canada Research Chair (CRC) in Placental Development and Maternal-Fetal Health. Dr. Gordon M. Keller holds a Tier 1 CRC in Embryonic Stem Cell Biology. Dr. Peter H. Backx holds a Tier 1 CRC in Cardiovascular Biology. Dr. Milica Radisic holds a Tier 2 CRC in Functional Cardiovascular Tissue Engineering.